1.
|
12 p, 608.0 KB |
Switching from a ritonavir-boosted protease inhibitor to a dolutegravir-based regimen for maintenance of HIV viral suppression in patients with high cardiovascular risk
/
Gatell, José Mª (Hospital Clínic i Provincial de Barcelona) ;
Assoumou, Lambert (UPMC Univ Paris 06) ;
Moyle, Graeme (St Chelsea and Westminster Hospital) ;
Waters, Laura (Mortimer Market Center) ;
Johnson, Margaret (Royal Free Hospital) ;
Domingo, Pere (Institut d'Investigació Biomèdica Sant Pau) ;
Fox, Julie (Guys and St. Thomas Hospital) ;
Martinez, Esteban (Hospital Clínic i Provincial de Barcelona) ;
Stellbrink, Hans-Jürgen (ICH Study Centrum) ;
Guaraldi, Giovanni (University of Modena and Reggio Emilia) ;
Masia, Mar (Hospital General Universitario de Elche) ;
Gompels, Marl (Southmead Hospital) ;
De Wit, Stephane (Université Libre de Bruxelles) ;
Florence, Eric (Institute of Tropical Medicine) ;
Esser, Stefan (Universitatsklinikum) ;
Raffi, François (CHU de Nantes) ;
Pozniak, Anton L. (St Chelsea and Westminster Hospital) ;
Universitat Autònoma de Barcelona
To compare the efficacy, safety, and impact on lipid fractions of switching from a ritonavir-boosted protease inhibitor (PI/r) to a dolutegravir (DTG) regimen. HIV type 1-infected adults more than 50 years or with a Framingham score more than 10% were eligible if plasma HIV RNA less than 50 copies per ml for at least 24 weeks while on a PI/r regimen. [...]
2017 - 10.1097/QAD.0000000000001675
AIDS, Vol. 31 Núm. 18 (28 2017) , p. 2503-2514
|
|
2.
|
12 p, 780.3 KB |
Observational cohort study of rilpivirine (RPV) utilization in Europe
/
Cozzi-Lepri, Alessandro (Centre for Clinical Research. Epidemiology. Modelling and Evaluation (CREME). Institute for Global Health. University College London) ;
Peters, Lars (CHIP. Rigshospitalet. University of Copenhagen) ;
Pelchen-Matthews, Annegret (Centre for Clinical Research. Epidemiology. Modelling and Evaluation (CREME). Institute for Global Health. University College London) ;
Neesgaard, Bastian (CHIP. Rigshospitalet. University of Copenhagen (Belgium)) ;
De Wit, Stéphane (Université Libre de Bruxelles, Department of Infectious Diseases) ;
Johansen, Isik Somuncu (Odense University Hospital (Dinamarca)) ;
Edwards, Simon (Mortimer Market Centre, Department of HIV (London)) ;
Stephan, Christoph (Infectious Diseases Unit. Goethe-University Hospital) ;
Adamis, Georgios (General Hospital of Athens G. Gennimatas (Greece)) ;
Staub, Therese (Centre Hospitalier de Luxembourg, Service des Maladies Infectieuses (Luxembourg)) ;
Zagalo, Alexandra (Santa Maria University Hospital, Department of Infectious Diseases (Lisbon, Portugal)) ;
Domingo, Pere (Institut d'Investigació Biomèdica Sant Pau) ;
Elbirt, Daniel (Allergy. Immunology and HIV Unit | Kaplan. Medical Center) ;
Kusejko, Katharina (University Hospital Zürich (Switzerland)) ;
Brännström, Johanna (Department of Infectious Diseases. Venhälsan Södersjukhuset) ;
Paduta, Dzmitry (Gomel Regional Centre for Hygiene) ;
Trofimova, Tatyana (Novgorod Centre for AIDS Prevention and Control) ;
Szlavik, Janos (South-Pest Hospital Centre-National Institute for Infectiology and Haematology) ;
Zilmer, Kai (West-Tallinn Central Hospital, Infectious Diseases Clinic (Talinn, Estonia)) ;
Losso, Marcello (Hospital J.M. Ramos Mejia (Buenos Aires)) ;
Van Eygen, Veerle (Janssen Research & Development) ;
Pai, Helen (Janssen Research & Development) ;
Lundgren, Jens (CHIP. Rigshospitalet. University of Copenhagen) ;
Mocroft, Amanda (Rigshospitalet. University of Copenhagen (Denmark)) ;
Harxhi, Arjan (Medical University of Tirana (Albania)) ;
Losso, Marcelo Horacio (Hospital General de Agudos JM Ramos Mejía (Buenos Aires)) ;
Kundro, Mariana (Hospital General de Agudos JM Ramos Mejía (Buenos Aires)) ;
Schmied, Brigitte (Institute of Science and Technology Austria (ISTA)) ;
Karpov, Igor Alexandrovich (Belarusian State Medical University (Minsk)) ;
Vassilenko, Anna (Belarusian State Medical University (Minsk)) ;
Paduto, Dmitriy (Regional AIDS Centre (Svetlogorsk, Bèlgica)) ;
Mitsura, Victor (Gomel State Medical University) ;
Clumeck, Nathan (University Hospital Brussels) ;
De Wit, Stéphane A. (Université Libre de Bruxelles) ;
Delforge, Marc D. (Université Libre de Bruxelles) ;
Hadziosmanovic, Vesnadarjan (Clinical Center University of Sarajevo) ;
Begovac, Josip (University of Zagreb) ;
Machala, Ladislav (Charles University in Prague) ;
Jilich, David (Charles University in Prague) ;
Gerstoft, Jan (IT University of Copenhagen) ;
Torp-Pedersen, Christian (Aalborg Universitet) ;
Sedlacek, Dalibor (Fakultní nemocnice Plzeň) ;
Kronborg, Gitte (University of Copenhagen) ;
Benfield, Thomas (Copenhagen University Hospital Hvidovre) ;
Johansen, IS (Odense University Hospital (Dinamarca)) ;
Ostergaard, Leif (Aarhus University) ;
Wiese, Lothar (Roskilde University) ;
Friis-Moller, Nina (Zealand University Hospital) ;
Nielsen, Lars Norregård (Hillerod Hospital (Hillerod, Dinamarca)) ;
Zilmer, Kai (Kaunas University of Technology) ;
Smidt, Jelena (Kohtla - Jarve Jarve Gümnaasium) ;
Aho, Inka (Helsinki University Central Hospital) ;
Viard, Jean-Paul (Université Paris Cité) ;
Girard, Pierre-Marie (University of Paris-Est) ;
Pradier, Christian (Centre Hospitalier Universitaire de Nice) ;
Fontas, Eric (Centre Hospitalier Universitaire de Nice) ;
Duvivier, Claudine (Hôpital Universitaire Necker) ;
Rockstroh, Jurgen (Universitätsklinikum Bonn) ;
Degen, Olaf (University Medical Center Hamburg) ;
Hoffmann, C. (IPM Study Center) ;
Stellbrink, H.J. (IPM Study Center) ;
Stefan, C. (JW Goethe University Hospital (Frankfurt)) ;
Bogner, Johannes (University Hospital München) ;
Fätkenheuer, Gerd (University of Cologne) ;
Chkhartishvili, N. (Infectious Diseases, AIDS and Clinical Immunology Research Center) ;
Sambatakou, Helen (Hippokration General Hospital (Athens)) ;
Paissios, N. (Athens General Hospital "G Gennimatas") ;
Uzdaviniene, V. (Vilnius University Hospital Santariskiu Clinics) ;
Staub, T. (Centre Hospitalier de Luxembourg) ;
Dragas, S. ;
Reiss, P. (University of Amsterdam) ;
Trajanovska, J. (University Clinic for Infectious Diseases & Febrile Conditions (Skopje)) ;
Reikvam, Dag Henrik (Oslo University Hospital (Oslo, Noruega)) ;
Maeland, A. (Oslo University Hospital (Oslo, Noruega)) ;
Bruun, Johan (University Hospital of North Norway) ;
Knysz, B. (WWF Poland) ;
Szetela, Bartosz (Nicolaus Copernicus University) ;
Inglot, Malgorzata (Wroclaw Medical University) ;
Bakowska, E. (Hospital For Infectious Diseases (Warsaw)) ;
Flisiak, Robert (Medical University of Bialystok) ;
Grzeszczuk, Anna (Medical University of Bialystok) ;
Parczewski, Miłosz (Pomeranian Medical University in Szczecin) ;
Maciejewska, Katarzyna (Pomeranian Medical University in Szczecin) ;
Aksak-Was, Bogusz (Pomeranian Medical University in Szczecin) ;
Beniowski, Marek (Medical University of Silesia in Katowice) ;
Mularska, Elżbieta ;
Jablonowska, Elżbieta (University of Lodz) ;
Kamerys, J. (Poznan University of Medical Sciences) ;
Wojcik, K. (University of Lodz) ;
Mozer-Lisewska, Iwona (Uniwersytet Medyczny im.Karola Marcinkowskiego w Poznaniu) ;
Rozplochowski, Błażej (Poznan University of Medical Sciences) ;
Zagalo, A. (Hospital Santa Maria (Lisboa, Portugal)) ;
Radoi, Roxana (Clinical Hospital Of Infectious Diseases "Dr. Victor Babes") ;
Oprea, Cris (Joint Institute for Nuclear Research) ;
Yakovlev, A. (Saint Petersburg State University) ;
Trofimora, T. (Novgorod Centre for AIDS (Novgorod)) ;
Khromova, I. (Tomsk Regional Center of AIDS and infectious diseases prophylaxis and control" (RCAIDPC)) ;
Kuzovatova, Elena (Blokhina Scientific Research Institute of Epidemiology and Microbiology of Nizhny Novgorod) ;
Borodulina, Elena (Samara State Medical University) ;
Vdoushkina, Elena (Samara State Medical University) ;
Ranin, Jovan (Klinički centar Srbije) ;
Tomazic, J. (Ljubljana University Medical Centre) ;
Miro, Josep M. (Instituto de Salud Carlos III) ;
Laguno, Montse (Hospital Clínic i Provincial de Barcelona) ;
Martinez, E. (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Garcia, F. (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Blanco, J.L. (Hospital Clínic i Provincial de Barcelona) ;
Martinez-Rebollar, María (Hospital Clínic i Provincial de Barcelona) ;
Mallolas Masferrer, Josep (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Callau, Pilar (Universitat de Barcelona) ;
Rojas, J. (Hospital Clínic i Provincial de Barcelona) ;
Moreno, Santiago (Pontifical Catholic University of Argentina) ;
del Campo, Santos (Hospital Universitario Ramón y Cajal (Madrid)) ;
Jou, A. (IrsiCaixa Institute for AIDS Research) ;
Paredes, Roger (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Puig, Jordi (Universitat Autònoma de Barcelona) ;
Llibre, Josep M.. (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Santos, J.R. (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Domingo, Pere (Hospital de la Santa Creu i Sant Pau (Barcelona, Catalunya)) ;
Gutierrez, M. (Hospital de la Santa Creu i Sant Pau (Barcelona, Catalunya)) ;
Mateo, G.M. (Hospital de la Santa Creu i Sant Pau (Barcelona, Catalunya)) ;
Sambeat, A. (Hospital de la Santa Creu i Sant Pau (Barcelona, Catalunya)) ;
Laporte, J.M. (Arabako Unibertsitate Ospitalea (Vitoria, País Basc)) ;
Svedhem, V. (Karolinska University Hospital and Karolinska Institutet (Suècia)) ;
Thalme, Anders (Karolinska University Hospital and Karolinska Institutet (Suècia)) ;
Sonnerborg, A. (Karolinska University Hospital) ;
Flamholc, L. (Skåne University Hospital (Suècia)) ;
Kusejko, Katharina (University of Zurich) ;
Weber, R. (Universitäts-Herzzentrum Freiburg - Bad Krozingen) ;
Calmy, Alexandra (University of Geneva) ;
Furrer, Hansjakob (Inselspital, Universitätsspital Bern) ;
Battegay, Manuel (University of Basel) ;
Schmid, P. (Cantonal Hospital of Schwyz) ;
Kuznetsova, A. (Kyiv National Economic University) ;
Mikhalik, Julia (Crimean Republican AIDS centre) ;
Sluzhynska, M. (International HIV/AIDS Alliance in Ukraine) ;
Milinkovic, Ana (Imperial College London) ;
Johnson, A.M. (Mortimer Market Centre) ;
Simons, Edwards (Mortimer Market Centre) ;
Edwards, S. (Brookhaven National Laboratory) ;
Phillips, A.M. (Royal Free and University College Medical School) ;
Johnson, M.A. (Royal Free and University College Medical School) ;
Mocroft, A. (Royal Free and University College Medical School) ;
Orkin, Chloe (Queen Mary, University of London) ;
Winston, Alan (Imperial College London) ;
Clarke, A. (University of Sussex) ;
Leen, Clifford (The University of Edinburgh)
Introduction: Data on safety and effectiveness of RPV from the real-world setting as well as comparisons with other NNRTIs such as efavirenz (EFV) remain scarce. Methods: Participants of EuroSIDA were included if they had started a RPV- or an EFV-containing regimen over November 2011-December 2017. [...]
2022 - 10.1186/s12981-022-00457-0
AIDS Research and Therapy, Vol. 19 Núm. 1 (december 2022) , p. 38
|
|
3.
|
16 p, 1.2 MB |
Impact of CD4 and CD8 dynamics and viral rebounds on loss of virological control in HIV controllers
/
Chereau, Fanny (Université Paris-Saclay) ;
Madec, Yoann (Institut Pasteur) ;
Sabin, Caroline A (Research Department of Infection and Population Health (Regne Unit)) ;
Obel, Niels (Copenhagen University Hospital Rigshospitalet) ;
Ruiz-Mateos, Ezequiel (Instituto de Biomedicina de Sevilla) ;
Chrysos, Georgios (Tzaneio General Hospital of Piraeus) ;
Fidler, Sarah (Imperial College (Regne Unit)) ;
Lehmann, Clara (University of Cologne and German Center for Infection Research) ;
Zangerle, Robert (DMedical University Innsbruck) ;
Wittkop, Linda (University Bordeaux) ;
Reiss, Peter (Stichting HIV Monitoring) ;
Hamouda, Osamah (Robert Koch Institute) ;
Estrada Perez, Vicente (Instituto de Investigación Sanitaria del Hospital Clínico San Carlos) ;
Leal, Manuel (Instituto de Biomedicina de Sevilla) ;
Mocroft, Amanda (Research Department of Infection and Population Health (Regne Unit)) ;
García de Olalla, Patricia (Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública) ;
Ammassari, Adriana (Istituto Nazionale Malattie Infettive) ;
D'Arminio Monforte, Antonella (University Hospital (Itàlia)) ;
Mussini, Cristina (University of Modena and Reggio Emilia) ;
Segura, Ferran (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT)) ;
Castagna, Antonella (San Raffaele Vita Salute University) ;
Cavassini, Matthias (Lausanne University Hospital) ;
Grabar, Sophie (Institut Pierre Louis d'Epidémiologie et de Santé Publique) ;
Morlat, Philippe (Université de Bordeaux) ;
De Wit, Stéphane (Université Libre de Bruxelles) ;
Lambotte, Olivier (Université Paris Sud) ;
Meyer, Laurence (Université Paris-Saclay) ;
Universitat Autònoma de Barcelona
HIV controllers (HICs) spontaneously maintain HIV viral replication at low level without antiretroviral therapy (ART), a small number of whom will eventually lose this ability to control HIV viremia. [...]
2017 - 10.1371/journal.pone.0173893
|
|
4.
|
13 p, 1.2 MB |
Body composition and adipokines changes after initial treatment with darunavir-ritonavir plus either raltegravir or tenofovir disoproxil fumarate-emtricitabine : A substudy of the NEAT001/ANRS143 randomised trial
/
Bernardino, J. I. (Hospital Universitario La Paz (Madrid)) ;
Mocroft, Amanda (University College London) ;
Wallet, C. (University of Bordeaux) ;
De Wit, Stéphane (CHU Saint Pierre, Brussels) ;
Katlama, C. (Hôpital Pitié Salpétrière, Paris) ;
Reiss, Peter (University of Amsterdam) ;
Mallon, P. W. (University College Dublin) ;
Richert, L. (University of Bordeaux) ;
Molina, J. M. (University of Paris Diderot) ;
Knobel Freud, Hernando (Hospital del Mar (Barcelona, Catalunya)) ;
Morlat, Philippe (CHU Bordeaux) ;
Babiker, A. (University College London) ;
Pozniac, A. (Chelsea and Westminster Hospital NHS Foundation Trust) ;
Raffi, F. (CHU de Nantes) ;
Arribas, Jose (Hospital Universitario La Paz (Madrid)) ;
Universitat Autònoma de Barcelona
Background Comparison of changes in body composition, adipokines and inflammatory markers after initial therapy with a nucleos(t)ide reverse transcriptase inhibitor (N(t)RTI)- sparing or containing regimen are scarce. [...]
2019 - 10.1371/journal.pone.0209911
PloS one, Vol. 14 Núm. 1 (january 2019) , p. e0209911
|
|
5.
|
11 p, 1.6 MB |
Week 96 efficacy and safety results of the phase 3, randomized EMERALD trial to evaluate switching from boosted-protease inhibitors plus emtricitabine/tenofovir disoproxil fumarate regimens to the once daily, single-tablet regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in treatment-experienced, virologically-suppressed adults living with HIV-1
/
Eron, J. J. (University of North Carolina School of Medicine) ;
Orkin, C. (Department of HIV Medicine. Royal Free London NHS Foundation Trust) ;
Cunningham, D. (Pueblo Family Physicians) ;
Pulido, F. (Hospital General Universitario de Alicante (Alacant, País Valencià)) ;
Post, F. (King's College Hospital NHS Foundation Trust) ;
De Wit, Stéphane (Université Libre de Bruxelles) ;
Lathouwers, E. (Janssen Pharmaceutica NV) ;
Hufkens, V. (Janssen Pharmaceutica NV) ;
Jezorwski, J. (Janssen Research & Development) ;
Petrovic, R. (Janssen Pharmaceutica NV) ;
Brown, K. (Janssen Pharmaceutica NV) ;
Van Landuyt, E. (Janssen Pharmaceutica NV) ;
Opsomer, M. (Janssen Pharmaceutica NV) ;
De Wit, Stéphane (Université Libre de Bruxelles) ;
Florence, E. (Institute of Tropical Medicine) ;
Moutschen, M. (Liège University Hospital (Bèlgica)) ;
Van Wijngaerden, E. (University Hospitals Leuven (Bèlgica)) ;
Vandekerckhove, L. (Ghent University Hospital. (Bèlgica)) ;
Vandercam, B. (AIDS Reference center. Cliniques Universitaires Saint-Luc) ;
Brunetta, J. (Maple Leaf Medical Clinic) ;
Conway, B. (Vancouver Infectious Diseases Center) ;
Klein, M. (Division of Infectious Diseases. Faculty of Medicine. McGill University Health Centre) ;
Murphy, D. (Institut national de santé publique du Québec) ;
Rachlis, A. (Sunnybrook Health Sciences Centre) ;
Shafran, S. (Department of Medicine. University of Alberta) ;
Walmsley, S. (University Health Network) ;
Ajana, F. (Infectious Diseases Department. Tourcoing Hospital) ;
Cotte, L. (Hospices Civils de Lyon. Hôpital de la Croix-Rousse) ;
Girardy, P. M. (University Pierre & Marie Curie) ;
Katlama, C. (HIV Clinical Research Unit) ;
Molina, J. M. (Department of Infectious Diseases. St-Louis Hospital APHP. University of Paris Diderot) ;
Poizot-Martin, I. (Clinical Immuno-Hematology Department. Aix-Marseille University. Sainte-Marguerite University Hospital and Inserm U912) ;
Raffi, F. (CHU Hôtel Dieu) ;
Rey, D. (Le Trait d'Union. HIV-Infection Care Center. Hôpitaux Universitaires de Strasbourg) ;
Reynes, J. (University Hospital of Montpellier (França)) ;
Teicher, E. (Infectious Diseases Department. APHP. Hôpital Bicêtre) ;
Yazdanpanah, Y. ;
Gasiorowski, J. (Independent Laboratory for Monitoring Infections among Drug Users at the Department of Infectious Diseases. Liver Disease and Acquired Immune Deficiencies. Wroclaw Medical University) ;
Halota, W. (Department of Infectious Diseases and Hepatology. Nicolaus Copernicus University) ;
Horban, A. (Medical University of Warsaw. Department for Adult's Infectious Diseases) ;
Piekarska, A. (Department of Infectious Diseases and Hepatology. Medical University of Lodz) ;
Witor, A. (Regional Hospital. Out-Patient's Clinic for Immune Deficiency) ;
Arribas, Jose (Instituto de Investigación Sanitaria del Hospital Universitario La Paz) ;
Perez-Valero, I. (Hospital Universitario La Paz (Madrid)) ;
Berenguer, Juan (Hospital General Universitario Gregorio Marañón) ;
Casado, José A. (Hospital Universitario Ramón y Cajal (Madrid)) ;
Gatell, J. M. (Infectious Diseases Department. HCB) ;
Gutiérrez, Félix (Hospital General Universitario de Elche) ;
Galindo, María José (Hospital Clínic Universitari (València)) ;
Gutiérrez Macià, Mª Del Mar (Institut d'Investigació Biomèdica Sant Pau) ;
Iribarren, J. A. (Hospital Universitario de Donostia (Sant Sebastià, País Basc)) ;
Knobel Freud, Hernando (Hospital del Mar (Barcelona, Catalunya)) ;
Negredo Puigmal, Eugènia. (Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa) ;
Pineda, J. A. (Hospital Universitario Virgen de Valme (Sevilla, Andalusia)) ;
Podzamczer, Daniel (Institut d'Investigació Biomèdica de Bellvitge) ;
Sogorb, J. P. (Hospital Universitario 12 de Octubre (Madrid)) ;
Pulido, F. (Hospital General Universitario de Alicante (Alacant, País Valencià)) ;
Ricart, C. (Department of Microbiology. School of Medicine. University of Valencia) ;
Rivero Román, Antonio (Hospital Universitario Reina Sofía (Còrdova, Espanya)) ;
Santos Gil, I. (Hospital Universitario de la Princesa (Madrid)) ;
Blaxhult, A. (Department of Infectious Diseases. Venhälsan. Södersjukhuset) ;
Flamholc, L. (Skåne University Hospital (Suècia)) ;
Gisslèn, M. (Department of Infectious Diseases. University of Gothenburg) ;
Thalme, A. (Karolinska University Hospital and Karolinska Institutet (Suècia)) ;
Fehr, J. (University Hospital Zurich (Suïssa)) ;
Rauch, A. (Bern University Hospital) ;
Stoeckle, M. (University Hospital Basel (Basilea, Suïssa)) ;
Clarke, A. (Claude Nicol Centre. Royal Sussex County Hospital. Brighton and Sussex University Hospitals NHS Trust) ;
Gazzard, B. G. (St. Stephen's Centre. Department of HIV/Genito-Urinary Medicine. Chelsea and Westminster Hospital) ;
Johnson, M. A. (Queen Mary University) ;
Orkin, C. (Department of HIV Medicine. Royal Free London NHS Foundation Trust) ;
Post, F. (King's College Hospital NHS Foundation Trust) ;
Ustianowski, Andrew (Regional Infectious Diseases Unit. North Manchester General Hospital) ;
Waters, L. (University College London Hospital) ;
Bailey, J. (Department of Medicine. Johns Hopkins University School of Medicine) ;
Benson, P. (Be Well Medical) ;
Bhatti, L. (AIDS Healthcare Foundation) ;
Brar, I. (Henry Ford Hospital) ;
Bredeek, U. F. (Metropolis Medical PC) ;
Brinson, C. (Central Texas Clinical Research) ;
Crofoot, G. (The Crofoot Research Center) ;
Cunningham, D. (Pueblo Family Physicians) ;
DeJesus, E. (Pueblo Family Physicians) ;
Dietz, C. (Orlando Immunology Center) ;
Dretler, R. (HIV Medicine. Kansas City Free Health Clinic) ;
Eron, J. (Infectious Disease Specialists of Atlanta) ;
Felizarta, F. (Private Practice) ;
Fichtenbaum, C. (University of Cincinnati College of Medicine) ;
Gallant, J. (Southwest CARE Center) ;
Gathe, J. (Therapeutic Concepts) ;
Hagins, D. (Georgia Department of Public Health. Chatham Care Center) ;
Henn, S. (Whitman-Walker Health) ;
Henry, W. K. (Department of Medicine. University of Minnesota Washington University School of Medicine) ;
Huhn, G. (Ruth M. Rothstein CORE Center) ;
Jain, M. (Department of Internal Medicine. University of Texas Southwestern Medical Center) ;
Lucasti, C. (South Jersey Infectious Disease) ;
Martorell, C. (Infectious Disease and The Research Institute) ;
McDonald, C. (Tarrant County Infectious Disease Associates) ;
Mills, A. (Southern California Men's Medical Group) ;
Morales-Ramirez, J. (Clinical Research Puerto Rico Inc.) ;
Mounzer, K. (Philadelphia FIGHT) ;
Nahass, R. (ID Care) ;
Olivet, H. (Community Research Initiative of New England) ;
Osiyemi, O. (Triple O Research Institute PA) ;
Prelutsky, D. (Department of Internal Medicine. Washington University School of Medicine) ;
Ramgopal, M. (Midway Immunology Center. Fort Pierce) ;
Rashbaum, B. (Capital Medical Associates) ;
Richmond, G. (Broward General Medical Center) ;
Ruane, P. (Ruane Clinical Research Group) ;
Scarsella, A. (Pacific Oaks Medical Group) ;
Scribner, A. (DCOL Center for Clinical Research) ;
Shalit, P. (Peter Shalit MD and Associates) ;
Shamblaw, D. (La Playa Medical Group) ;
Slim, J. (Department of Infectious Diseases. Seton Hall University) ;
Tashima, K. (The Miriam Hospital. Warren Alpert Medical School of Brown University) ;
Voskuhl, G. (AIDS Arms. Inc.) ;
Ward, D. (Dupont Circle Physicians Group) ;
Wilkin, A. (Wake Forest School of Medicine) ;
de Vente, J. (Living Hope Foundation) ;
Universitat Autònoma de Barcelona
Darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) 800/150/200/10 mg was investigated through 96 weeks in EMERALD (NCT02269917). Virologically-suppressed, HIV-1-positive treatment-experienced adults (previous non-darunavir virologic failure [VF] allowed) were randomized (2:1) to D/C/F/TAF or boosted protease inhibitor (PI) plus emtricitabine/tenofovir-disoproxil-fumarate (F/TDF) over 48 weeks. [...]
2019 - 10.1016/j.antiviral.2019.104543
Antiviral Research, Vol. 170 (october 2019) , p. 104543
|
|